

John Ravits

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11693162/publications.pdf>

Version: 2024-02-01

35
papers

6,826
citations

257101

24
h-index

395343

33
g-index

36
all docs

36
docs citations

36
times ranked

8061
citing authors

#	ARTICLE	IF	CITATIONS
1	Pathological TDP-43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations. <i>Annals of Neurology</i> , 2007, 61, 427-434.	2.8	840
2	Divergent roles of ALS-linked proteins FUS/TLS and TDP-43 intersect in processing long pre-mRNAs. <i>Nature Neuroscience</i> , 2012, 15, 1488-1497.	7.1	628
3	Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial. <i>Lancet Neurology</i> , The, 2007, 6, 1045-1053.	4.9	610
4	Targeting RNA Foci in iPSC-Derived Motor Neurons from ALS Patients with a C9ORF72 Repeat Expansion. <i>Science Translational Medicine</i> , 2013, 5, 208ra149.	5.8	586
5	Targeted degradation of sense and antisense C9orf72 RNA foci as therapy for ALS and frontotemporal degeneration. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, E4530-9.	3.3	508
6	Controversies and priorities in amyotrophic lateral sclerosis. <i>Lancet Neurology</i> , The, 2013, 12, 310-322.	4.9	454
7	RIPK1 mediates axonal degeneration by promoting inflammation and necroptosis in ALS. <i>Science</i> , 2016, 353, 603-608.	6.0	448
8	Gain of Toxicity from ALS/FTD-Linked Repeat Expansions in C9ORF72 Is Alleviated by Antisense Oligonucleotides Targeting GGGGCC-Containing RNAs. <i>Neuron</i> , 2016, 90, 535-550.	3.8	437
9	A Long-Term Follow-up Study of Patients with Post-Poliomyelitis Neuromuscular Symptoms. <i>New England Journal of Medicine</i> , 1986, 314, 959-963.	13.9	350
10	Premature polyadenylation-mediated loss of stathmin-2 is a hallmark of TDP-43-dependent neurodegeneration. <i>Nature Neuroscience</i> , 2019, 22, 180-190.	7.1	345
11	Neuropathology of Amyotrophic Lateral Sclerosis and Its Variants. <i>Neurologic Clinics</i> , 2015, 33, 855-876.	0.8	199
12	Reduced C9ORF72 function exacerbates gain of toxicity from ALS/FTD-causing repeat expansion in C9orf72. <i>Nature Neuroscience</i> , 2020, 23, 615-624.	7.1	157
13	Sense-encoded poly-GR dipeptide repeat proteins correlate to neurodegeneration and uniquely co-localize with TDP-43 in dendrites of repeat-expanded C9orf72 amyotrophic lateral sclerosis. <i>Acta Neuropathologica</i> , 2018, 135, 459-474.	3.9	152
14	Implications of ALS focality: Rostral-caudal distribution of lower motor neuron loss postmortem. <i>Neurology</i> , 2007, 68, 1576-1582.	1.5	142
15	Deciphering amyotrophic lateral sclerosis: What phenotype, neuropathology and genetics are telling us about pathogenesis. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2013, 14, 5-18.	1.1	142
16	Distinct and shared functions of ALS-associated proteins TDP-43, FUS and TAF15 revealed by multisystem analyses. <i>Nature Communications</i> , 2016, 7, 12143.	5.8	137
17	Sporadic ALS has compartment-specific aberrant exon splicing and altered cell matrix adhesion biology. <i>Human Molecular Genetics</i> , 2010, 19, 313-328.	1.4	114
18	Focality, stochasticity and neuroanatomic propagation in ALS pathogenesis. <i>Experimental Neurology</i> , 2014, 262, 121-126.	2.0	81

#	ARTICLE	IF	CITATIONS
19	Transcriptome-pathology correlation identifies interplay between TDP-43 and the expression of its kinase CK1E in sporadic ALS. <i>Acta Neuropathologica</i> , 2018, 136, 405-423.	3.9	69
20	Pathological TDP-43 changes in Betz cells differ from those in bulbar and spinal \pm -motoneurons in sporadic amyotrophic lateral sclerosis. <i>Acta Neuropathologica</i> , 2017, 133, 79-90.	3.9	68
21	Aberrant Neuregulin 1 Signaling in Amyotrophic Lateral Sclerosis. <i>Journal of Neuropathology and Experimental Neurology</i> , 2012, 71, 104-115.	0.9	62
22	Lack of C9ORF72 coding mutations supports a gain of function for repeat expansions in amyotrophic lateral sclerosis. <i>Neurobiology of Aging</i> , 2013, 34, 2234.e13-2234.e19.	1.5	59
23	Clinical and electromyographic studies of postpoliomyelitis muscular atrophy. <i>Muscle and Nerve</i> , 1990, 13, 667-674.	1.0	44
24	Cross-Comparison of Human iPSC Motor Neuron Models of Familial and Sporadic ALS Reveals Early and Convergent Transcriptomic Disease Signatures. <i>Cell Systems</i> , 2021, 12, 159-175.e9.	2.9	33
25	Pathogenic Mechanisms and Therapy Development for C9orf72 Amyotrophic Lateral Sclerosis/Frontotemporal Dementia. <i>Neurotherapeutics</i> , 2019, 16, 1115-1132.	2.1	30
26	TDP-43 protein variants as biomarkers in amyotrophic lateral sclerosis. <i>BMC Neuroscience</i> , 2017, 18, 20.	0.8	27
27	An integrated multi-omic analysis of iPSC-derived motor neurons from C9ORF72 ALS patients. <i>IScience</i> , 2021, 24, 103221.	1.9	27
28	Antisense RNA foci are associated with nucleoli and TDP-43 mislocalization in C9orf72-ALS/FTD: a quantitative study. <i>Acta Neuropathologica</i> , 2019, 137, 527-530.	3.9	21
29	TDP-43 and ubiquitinated cytoplasmic aggregates in sporadic ALS are low frequency and widely distributed in the lower motor neuron columns independent of disease spread. <i>Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders</i> , 2010, 11, 321-327.	2.3	20
30	Nuclear RIPK1 promotes chromatin remodeling to mediate inflammatory response. <i>Cell Research</i> , 2022, 32, 621-637.	5.7	18
31	Predicting disease specific spinal motor neurons and glia in sporadic ALS. <i>Neurobiology of Disease</i> , 2019, 130, 104523.	2.1	10
32	Kinnier Wilson's puzzling features of amyotrophic lateral sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, 657-666.	0.9	4
33	Delivering Bad News in Amyotrophic Lateral Sclerosis. <i>Neurology: Clinical Practice</i> , 2021, 11, 521-526.	0.8	3
34	Unraveling molecular biology of C9ORF72 repeat expansions in amyotrophic lateral sclerosis-frontotemporal dementia: Implications for therapy. , 2021, , 19-47.		0
35	Sleep Apnea in Familial Dysautonomia: A Reflection of Apnea Pathogenesis. <i>Journal of Clinical Sleep Medicine</i> , 2016, 12, 1583-1584.	1.4	0